Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,801–1,871 of 1,871
Tănăsescu, M., Rosu, A.-M., Mincă, A., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026) · Life · doi:10.3390/life16050756 · Cited by 1
“Nevertheless, the broader class profile remains less uniform than that of SGLT-2 inhibitors in dedicated cardiorenal settings [61].”
Chechulina, V., Clemens, K. K., Vinson, A. J., Chiu, M., Young, A., MOIST, L. M., & for the OK TRANSPLANT Investigators (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581261454465
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Ena, J., Carretero‐Gómez, J., Tembra, M. S., Villar, L. L., Peña, C. F., Rosales‐Castillo, A., Domínguez‐Pinilla, N., Carrasco-Sánchez, F. J., Bustos-Merlo, A., & Soler, A. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.01.003 · Cited by 2
Chen, S.-C., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., & Su, P. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002132 · Cited by 2
“24 Our real-world, nondiabetic cohort likely sits at a different place on the risk spectrum, which may explain the comparatively muted renal biomarker separation across drugs in the near term.”
Inker, L. A., Greene, T., Chertow, G. M., Damron, K. C., Furberg, J. F., Gasparyan, S. B., Gordon, C., Guðmundsdóttir, H., Heerspink, H. J. L., Jongs, N., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.06.017
Abdalla, S. A. M., Mohammed, H. O. A., Omer, E. O. E., Ahmed, I. O. I., Ahmed, W. A. O., Ginawi, K. O. T., Abdelfattah, R. E. M., Yousif, A. A. Z., & Ismail, K. I. A. (2026) · Cureus · doi:10.7759/cureus.111723
“The FLOW trial, which was excluded because its primary endpoint was a kidney composite, established that semaglutide reduces major kidney disease events in T2DM and chronic kidney disease [26].”
Causal Effects of Early Discontinuation of Proton Pump Inhibitors on Kidney Failure
Kawano, Y., Oka, T., Sakaguchi, Y., Kadono, H., Uwatoko, R., Fukuda, S., Doi, Y., Hashimoto, N., Kusunoki, Y., Yamamoto, S., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106709 · Cited by 1
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
PET-Derived Renal Perfusion Provides a Window Into Cardiorenal Risk Beyond Filtration
Patel, K. K., & Dilsizian (2026) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.126.019570
Sztefka, D., Jaunich, A., Szlachetka, K., & Zając, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5402
Bandaranaike, R., Rutland, T., & Rutland, B. (2026) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1502
Komatsu, M., Kobayashi, H., Tsuboi, S., & Watada, H. (2026) · Diabetology International · doi:10.1007/s13340-026-00877-7
Chen, G., Zheng, H., Wang, Y., 桂曼, He, Z., Chen, Z., Wu, S. L., & Chen, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1812122
Verlaan, J. P. L., van Es, N., & Scheres, L. J. J. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.035
The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists
Bradwisch, S. A., Smith, E. M., Wilson-Mooney, C., & Donahue-Stathis, C. (2025) · Nursing · doi:10.1097/nsg.0000000000000223 · Cited by 1
Mesgar, M. H., Dortāj, F., Ghaemi, F., Jahromi, R. G., & Shamir, A. S. (2026) · Journal of Health Research and Development · doi:10.66224/jhrd.4.2.30
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Are we closer to surpassing residual renal risk in type 2 diabetes?
Karalliedde, J. J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00101-4
Wang, T., & Du, Y. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00938-8
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01461-y
The synergistic treatment of heart and kidney disease
Mahfoud, F., Götzinger, F., Kramann, R., Marx, N., & Schwenger, V. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0131 · Cited by 1
Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients
Tyurina, A. V., Kurochkina, N. S., & Владиславович, Е. М. (2026) · Kardiologiia · doi:10.18087/cardio.2026.2.n3116 · Cited by 1
GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes?
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00399-1
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Muzurović, E. M., Zečević, K., & Mikhailidis, D. P. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02367-3
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review
Soto-Santillán, P., Jacobo-Ruvalcaba, A., de Lay, M. W., & Orihuela-Rodríguez, Ó. (2026) · Biomedicines · doi:10.3390/biomedicines14040841
Brandenburg, V. (2025) · Nephrologie aktuell · doi:10.1055/a-2511-0407
Trenas, A., Prieto-Laín, N., Gómez-Hernández, A. I., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19040583 · Cited by 1
“These effects are consistent across subgroups, including those with and without baseline HF or reduced eGFR [22].”
InfluentialAlam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
GLP-1 Receptor Agonists, Lithium, and the Kidneys: A Tale of Two Signals
Leung, J. G., & Singh, B. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002253 · Cited by 1
Research progress in precision medicine for type 2 diabetes based on the GLP-1
Wang, S., Yuan, C., Wang, H., Ye, X., Ruan, S., Yi, L., Yang, W., Wang, Z., Wang, N., Li, J., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1721842 · Cited by 2
Kosobutskaya, S. A., Ausheva, D. K., Amirova, M. A., Belaya, M. V., Startseva, S. A., Samokhina, A. A., Vasileva, Y. A., Kochetkova, S. A., Tsomaev, B. P., Dzgoev, G. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.363
Campos, C., King, A., Miller, E. M., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0040 · Cited by 1
Assessment and management of albuminuria in adults
Claudel, S. E., Kar, D., Majeed, A., Burgwinkle, P. S., & Verma, A. (2025) · BMJ · doi:10.1136/bmj-2025-084911 · Cited by 1
Peripheral artery disease: advances in medical therapy
Garagoli, F., Slipczuk, L. N., Shapiro, M. D., Bonaca, M. P., & Bhatt, D. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag516 · Cited by 3
Ayusso, L. L., Girol, A. P., Neto, L. M., Gomes, I., & Burdmann, E. A. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0349pt
Tirzepatide and Kidney Protection in Obesity
Zhu, Z., & Ren, K. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000837
Kushner, P. R., & Mende, C. W. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0017 · Cited by 1
Semaglutide’s dilemma: A lifesaver with a price?
Dingal, N. S. (2025) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_19_25
Rallabandi, S., Sharma, M., Kosuru, K., & Kashyap, R. (2026) · Cureus · doi:10.7759/cureus.104376 · Cited by 3
“Studies even suggest that semaglutide may reduce the progression of nephropathy in patients with diabetes and chronic kidney disease, as reported in the semaglutide once weekly (FLOW) trial [14].”
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
Santamaria, R., Escobar, C., Aranda, U., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501414
Dato, A. D., Nardi, S., & Socci, C. (2025) · Updates in surgery/Updates in surgery series · doi:10.1007/978-3-031-92716-4_19
Angiopoietins: A potential therapeutic target in the treatment of diabetic nephropathy
Thapa, K., Kanojia, N., Khan, H., Kaur, A., & Singh, T. G. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100659
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Htoo, P. T., Cho, H., Paik, J. M., Bykov, K., Everett, B. M., Glynn, R. J., Shay, C. M., Schmedt, N., Wexler, D. J., & Patorno, E. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03287-w · Cited by 1
“Glu-cagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have each shown benefits in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and kidney disease progression [3–7].”
Macía-Heras, M., Hernández-Marrero, D. J., Martínez‐Alberto, C. E., Siverio-Morales, O., & Donate‐Correa, J. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05304-2
Sriperumbuduri, S., Khan, R. W., Aftab, S., Hiremath, S. S., Dixon, D. L., & Gupta, G. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag111
Preventative nephrology in the cardiovascular–kidney–metabolic era
Habte‐Asres, H. H., & Wheeler, D. C. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01140-7
К.О., П. (2026) · Український медичний часопис · doi:10.32471/umj.1680-3051.281001
Nuevos tratamientos farmacológicos en la enfermedad renal crónica: revisión sistemática
Urbano-Borja, N. D. C., Buenaño-Rosero, K. M., & Vásquez-Remachi, D. J. (2026) · Sanitas. Revista arbitrada de ciencias de la salud. · doi:10.62574/pk8fjw80
Arumapperuma, H., Tanaka, K., & Sy, J. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100164
Tratamiento farmacológico actual de la nefropatía diabética: revisión sistemática
Encalada-Bermeo, E. A., Bolaños-Soria, J. V., Gonzabay-Rosales, F. J., & Palacios-Puga, S. E. (2026) · Sanitas. Revista arbitrada de ciencias de la salud. · doi:10.62574/xd2tza21
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
Cai, Y., He, S., Zeng, F., & Liu, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1954392
Innovative holistic treatment for CKM: what lies ahead?
Balfanz, P., & Marx, N. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107222
Gargiulo, P., Marzano, F., Liccardi, L., Nodari, S., Cameli, M., Giallauria, F., Guerra, F., Imbalzano, E., Sinagra, G., Carugo, S., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107183
Mauriello, A., Cetoretta, V., Giudice, C. D., Correra, A., Maratea, A. C., Gioia, R., Liccardo, B., Esposito, G., Russo, V., & D’Andrea, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102257
Epelde, F. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1956165
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
“The t½ of Tirzepatide is approximately 116–120 h (5 days), which supports weekly dosing, whereas the t½ of liraglutide is about 13 h, necessitating daily administration [ 29, 30].”
Cahya, D. A., Dzulkarnain, S. A., Wrahatnala, B. J., Soraya, M., & Wahjuni, E. S. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3489
Sehtman-Shachar, D. R., Fishkin, A., Leibowitz, G., Mosenzon, O., Schechter, M., & Aharon‐Hananel, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71402
Lee, A. A., Borisov, D. О., Novikova, V. S., Kashirskikh, D. A., Khotina, V. A., Gasanov, V. A. O., & Vasiliev, A. V. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.412
Schlaich, M. P., Woodhams, L., Herat, L. Y., & Bell, D. A. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag090
Schumacher, L. M., Rodrigues, E., Mraz, E., Wohler, D., Rajpal, A., Herring, S. J., Rubin, D. J., Rao, A. D., Igarabuza, L., Flanagan, S. P., et al. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70199
“For example, some patients may benefit from certain GLP‐1 RAs as part of their kidney disease treatment or for the management of existing cardiovascular disease [32, 33].”
U.S. Trends in 10-Year Cardiovascular Risk Scores Over 2 Decades
Drexler, Y. R., Goldwasser, O., McCarley, C., Land, D., Naranjo, C., Mechery, V., Kulandavelu, S., Rundek, T., Yang, E., & Elfassy, T. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103307 · Cited by 1
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.